Advertisement

Burden of Inappropriate Prescription of Direct Oral Anticoagulants at Hospital Admission and Discharge in the Elderly: A Prospective Observational Multicenter Study

  • Antoine BruneauEmail author
  • Camille Schwab
  • Maud Anfosso
  • Christine Fernandez
  • Patrick Hindlet
Original Research Article
  • 50 Downloads

Abstract

Introduction

Direct oral anticoagulants (DOACs) were developed to overcome some of the limitations associated with vitamin K antagonists (VKAs), such as interindividual variability or the need for therapeutic drug monitoring. However, the complexity of DOAC dose regimens can still lead to dosing errors and potential bleeding-related or thromboembolic adverse events, especially in the elderly.

Objective

Our objective was to evaluate the rate of inappropriate preadmission DOAC prescriptions at hospital and to evaluate the ability of hospitals to correct them.

Methods

An observational prospective study was conducted in elderly patients (aged ≥ 65 years) hospitalized in six acute units of three Parisian university hospitals between February and July 2018. DOAC prescriptions prior to admission and at discharge were analyzed according to the guidelines in the summaries of product characteristics.

Results

A total of 157 patients were included in the study, with a median age of 84 years (interquartile range [IQR] 77–89). The median glomerular filtration rate, determined with the Cockcroft–Gault equation, was 48 mL/min (IQR 35–61). Apixaban was the most frequently prescribed drug, mainly for atrial fibrillation. Overall, 48 (30.6%) and 34 (22.4%) prescriptions were inappropriate prior to admission and at discharge, respectively, showing a significant decrease (p < 0.001). Hospitals significantly corrected more inappropriate prescriptions (37.5%) than they generated (4.6%) (p < 0.05). The nature of the inappropriate prescribing was underdosing (68.8% and 76.5% prior to admission and at discharge, respectively), followed by overdosing (stable rate at almost 20%) and indication errors. No risk factors for inappropriate use were identified by our analysis.

Conclusion

One-third of DOAC preadmission prescriptions for elderly patients were inappropriate, indicating that a need remains to strengthen DOAC prescribing guidelines in ambulatory clinical practice. However, the rate of inappropriate prescriptions decreased at patient discharge. Future studies are needed to test actions to promote the proper use of DOACs.

Notes

Acknowledgements

The authors gratefully acknowledge the pharmacists from the six centers for their participation in this study. The kind assistance of Stella Ghouti, qualified translator is also gratefully acknowledged.

Compliance with Ethical Standards

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

A. Bruneau, C. Schwab, M. Anfosso, C. Fernandez and P. Hindlet have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Supplementary material

40266_2019_710_MOESM1_ESM.pdf (132 kb)
Supplementary material 1 (PDF 132 kb)

References

  1. 1.
    Pradaxa® (dabigatran). Summary of Product Characteristics. Boehringer Ingelheim.Google Scholar
  2. 2.
    Xarelto® (rivaroxaban). Summary of Product Characteristics. Bayer Healthcare.Google Scholar
  3. 3.
    Eliquis® (apixaban). Summary of Product Characteristics. Bristol-Myers Squibb.Google Scholar
  4. 4.
    Connoly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefGoogle Scholar
  5. 5.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefGoogle Scholar
  6. 6.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefGoogle Scholar
  7. 7.
    Rapport d’évaluation des médicaments anticoagulants oraux. HAS, commission de la transparence. 2018.Google Scholar
  8. 8.
    Etude de l’Assurance Maladie sur l’utilisation des nouveaux anticoagulants oraux. Assurance Maladie. 2013.Google Scholar
  9. 9.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–88.CrossRefGoogle Scholar
  10. 10.
    Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.  https://doi.org/10.1016/S0140-6736(13)62343-0 (Epub 2013 Dec 4).CrossRefGoogle Scholar
  11. 11.
    Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation. Ann Pharmacother. 2018;52(2):147–53.CrossRefGoogle Scholar
  12. 12.
    Bourcier E, Mille F, Brunie V, et al. Quality of prescribing in community-dwelling elderly patients in France: an observational study in community pharmacies. Int J Clin Pharm. 2017;39(6):1220–7.  https://doi.org/10.1007/s11096-017-0531-6 (Epub 2017 Sep 14).CrossRefGoogle Scholar
  13. 13.
    Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):e002758.  https://doi.org/10.1136/bmjopen-2013-002758.CrossRefGoogle Scholar
  14. 14.
    Howard M, Lipshutz A, Roess B, et al. Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants. J Thromb Thrombolysis. 2017;43(2):149–56.CrossRefGoogle Scholar
  15. 15.
    Pattullo CS, Barras M, Tai B, et al. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J. 2016;46(7):812–8.CrossRefGoogle Scholar
  16. 16.
    Lafon T, Vallejo C, Hadj M, et al. Misuse and adverse effects of new direct oral anticoagulants: A prospective observational study in patients admitted to an emergency unit of a French university hospital. Therapie. 2018;73(3):209–15.CrossRefGoogle Scholar
  17. 17.
    Piau A, Huet Y, Gallini A, et al. Optimization of drug therapy in elderly individuals admitted to a geriatric unit. Clin Interv Aging. 2017;12:1691–6.CrossRefGoogle Scholar
  18. 18.
    Lee JK, Slack MK, Martin J, et al. Geriatric patient care by U.S. pharmacists in healthcare teams: systematic review and meta-analyses. J Am Geriatr Soc. 2013;61(7):1119–27.Google Scholar
  19. 19.
    Moudallel S, Steurbaut S, Cornu P, et al. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol. 2018;9:1220.  https://doi.org/10.3389/fphar.2018.01220 (eCollection 2018).CrossRefGoogle Scholar
  20. 20.
    Franchi C, Antoniazzi S, Proietti M, et al. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. Br J Clin Pharmacol. 2018;84(9):2010–9.  https://doi.org/10.1111/bcp.13631 (Epub 2018 Jun 19).CrossRefGoogle Scholar
  21. 21.
    Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–90.CrossRefGoogle Scholar
  22. 22.
    Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16(3):763–73.CrossRefGoogle Scholar
  23. 23.
    Pérez Cabeza AI, Chinchurreta Capote PA, Gonzalez Correa JA, et al. Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. Med Clin (Barc). 2018;150(3):85–91.CrossRefGoogle Scholar
  24. 24.
    Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3):476–84.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hôpitaux de Paris, Hôpital Saint-Antoine, Service de PharmacieParisFrance
  2. 2.Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, IPLESP UMR-S1136ParisFrance
  3. 3.Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de PharmacieParisFrance
  4. 4.Université Paris-Sud, Faculté de PharmacieChatenay-MalabryFrance

Personalised recommendations